When in combination with EGFR CAR-NKs, the therapy increased tumor cell death in vitro, and in vivo it promoted the suppression of tumor growth and greater survival in comparison to monotherapy, leading to higher intracranial infiltration and activation of NK cells and TCD8+ lymphocytes, as well as elevated persistence of the CAR-NK cells. This evidence concerns the gene EGFR and neoplasm.